| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Research Abstract |
To explore the molecular mechanisms of hormone sensitivity is important to improve the prognosis of hormone receptor (HR)+/HER2- breast cancer.
1) The expression of GATA-3, FOXA1 and AR was associated with good prognosis. FOXA1 is considered to be a good predictive marker of adjuvant endocrine therapy. 2) FOXA1 expression is reduced by neoadjuvant endocrine therapy, especially in tumors with low PEPI scores, suggesting FOXA1 is related to hormone sensitivity. 3) The prognosis of HR+ breast cancer with activated Akt had shorter overall survival. Akt activation is related to endocrine resistance. The better understanding of the molecular mechanisms of hormone sensitivity is necessary to improve the efficacy of endocrine therapy for breast cancer.
|
